Diaceutics (LON:DXRX) Hits New 1-Year High - Here's Why

Key Points

• Diaceutics PLC shares reached a new 52-week high of GBX 167 ($2.25), indicating positive market performance.
• Analysts have mixed ratings, with the Royal Bank of Canada lowering its target price to GBX 185 while Canaccord Genuity maintains a "buy" rating with a target of GBX 180.
• The company reported a negative EPS of GBX (2.84) in its last quarterly results, alongside a negative return on equity of 7.15% and a net margin of 10.90%.

Diaceutics PLC (LON:DXRX - Get Free Report) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as GBX 167 ($2.25) and last traded at GBX 165 ($2.22), with a volume of 190377 shares traded. The stock had previously closed at GBX 166 ($2.23).

Analyst Ratings Changes

DXRX has been the subject of several recent research reports. Royal Bank Of Canada reduced their target price on shares of Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating for the company in a report on Thursday, July 10th. Canaccord Genuity Group restated a "buy" rating and set a GBX 180 target price on shares of Diaceutics in a report on Tuesday, July 22nd. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of GBX 175.

Diaceutics Trading Down 0.6%

The firm has a market capitalization of £139.50 million, a P/E ratio of -8,168.32 and a beta of 0.58. The business's 50-day moving average is GBX 141.88 and its 200 day moving average is GBX 129.07. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92.

Diaceutics (LON:DXRX - Get Free Report) last released its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (2.84) EPS for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. As a group, analysts anticipate that Diaceutics PLC will post 1.0107919 EPS for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.